Suppr超能文献

[多灶性肺神经内分泌肿瘤:起源、诊断与治疗]

[Multifocal Pulmonary Neuroendocrine Tumours: Genesis, Diagnostics and Treatment].

作者信息

Kirschbaum A, Beutel B, Rinke A, Rexin P, Fink L, Koczulla R, Bartsch D K

机构信息

Klinik für Viszeral-, Thorax- und Gefäßchirurgie, Uniklinik Gießen und Marburg (UKGM), Standort Marburg.

Klinik für Pneumologie, Uniklinik Gießen und Marburg (UKGM), Standort Marburg.

出版信息

Pneumologie. 2016 Feb;70(2):123-9. doi: 10.1055/s-0041-110291. Epub 2016 Feb 19.

Abstract

Multifocal neuroendocrine lung tumour is a rare diagnosis. Multiple lung foci of different sizes are usually apparent on chest CT scans. It is assumed that multifocal neuroendocrine lung tumours originally develop from diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH). This results in cell aggregations formed by proliferation of neuroendocrine cells that are already physiologically present in the bronchial system. If these cell proliferations break through the bronchial basement membrane, they are considered to constitute tumourlets if they measure ≤ 5 mm and carcinoid tumours if they are larger than 5 mm. The speed of proliferation of the cell hyperplasias appears to vary. Many of the patients are completely asymptomatic, the multifocal neuroendocrine lung tumours being diagnosed by chance. However, other patients complain of breathlessness, reduced physical capacity and cough. There may also be reduction of lung function. In these cases, chest HRCT often reveals peribronchial fibrosis or bronchiectasis in addition to the lung foci. Bronchoscopy is usually not helpful. Surgical lung biopsy is considered to be the diagnostic gold standard. Histological examination typically shows a mixture of cell hyperplasias, tumourlets and carcinoid tumours. There is no consensus on the treatment of multifocal neuroendocrine tumours. Taking the clinical situation and the chest HRCT findings as our starting point, we developed a stepwise approach that is guided by the success of the individual therapeutic procedures. The most favourable prognosis is found in affected people without clinical symptoms whose lung foci all measure less than 5 mm. In these cases the 5-year survival rate is over 90%.

摘要

多灶性神经内分泌肺肿瘤是一种罕见的诊断。胸部CT扫描通常会显示出大小不同的多个肺部病灶。据推测,多灶性神经内分泌肺肿瘤最初起源于弥漫性特发性肺神经内分泌细胞增生(DIPNECH)。这导致了由支气管系统中原本就存在的神经内分泌细胞增殖形成的细胞聚集。如果这些细胞增殖突破支气管基底膜,直径≤5mm时被认为构成微瘤,大于5mm则被认为是类癌肿瘤。细胞增生的增殖速度似乎有所不同。许多患者完全没有症状,多灶性神经内分泌肺肿瘤是偶然被诊断出来的。然而,其他患者会抱怨呼吸急促、体力下降和咳嗽。肺功能也可能会下降。在这些情况下,胸部高分辨率CT(HRCT)除了肺部病灶外,还常常显示支气管周围纤维化或支气管扩张。支气管镜检查通常没有帮助。手术肺活检被认为是诊断的金标准。组织学检查通常显示细胞增生、微瘤和类癌肿瘤的混合。对于多灶性神经内分泌肿瘤的治疗尚无共识。以临床情况和胸部HRCT检查结果为出发点,我们制定了一种逐步的方法,该方法以个体治疗程序的成功为指导。预后最有利的是那些没有临床症状且肺部病灶均小于5mm的患者。在这些情况下,5年生存率超过90%。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验